Real‐world experiences of adult individuals or caregivers of children who received teplizumab treatment in stage 2 type 1 diabetes
Authors' conclusion
Individuals living with or caring for someone who received teplizumab felt grateful for the opportunity to delay disease or make it easier to manage following teplizumab, with most agreeing they would recommend teplizumab and make the same decision for family in their situation.
Study context
- Population
- Adults and caregivers of children who received teplizumab at stage 2 T1D in the US COMPASS patient support programof 116 invited
- Participants
- 47 adults
- Exposure
- Adults vs Caregivers
- Adultsn = 30
- Caregiversn = 17
- Outcome
- Real-world experiences and outlook after teplizumab
Methodological detailsobservational, online survey, Online survey conducted September-October 2024
- Observational
- Online survey
- Online survey conducted September-October 2024
Main finding
As reported in the abstract
Felt grateful to receive teplizumab
87%
Felt it would help slow down the disease
72%
Felt it would make T1D easier to manage
60%
Would recommend treatment/make the same decision for another family member
>80%
Observational data: associations, not effects.
Further findings
Respondent characteristics
- Family history of T1D
- Almost half
- Autoimmune comorbidities
- 36%
Original publication
Real‐world experiences of adult individuals or caregivers of children who received teplizumab treatment in stage 2 type 1 diabetes. Diabetes Obes Metab. Published 13 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →